



Molecular Stress Response Dysregulation in Cancer: Therapeutic Targets and Opportunities

Guest Editor:

Prof. Dr. Georg T. Wondrak

Department of Pharmacology
and Toxicology, College of
Pharmacy and UA Cancer Center,
University of Arizona, Tucson, AZ
85724, USA

Deadline for manuscript
submissions:

closed (1 April 2019)

Message from the Guest Editor

Dear Colleagues,

The paradoxical combination of an age-related increase in cancer incidence and a demographic shift towards senescent populations has greatly exacerbated the role of cancer as a major medical challenge of global proportions, creating an urgent need for the discovery of novel molecular cancer therapeutics. Seminal research has provided cumulative evidence that oncogene-driven tumorigenesis dictates the dysregulated occurrence of genotoxic, mitotic, metabolic, proteotoxic, immunomodulatory, and redox stress responses. On the other hand, tumorigenic progression depends on the counter-regulatory activation of cytoprotective stress response pathways that represent a specific mechanistic vulnerability amenable to therapeutic intervention by molecularly targeted therapeutics. This special issue gathers original research and review papers positioned at the forefront of our current understanding of molecular stress response dysregulation in cancer, representing both a major pathological driving force and promising therapeutic target.

Dr. Georg T. Wondrak

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)